Spots Global Cancer Trial Database for MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

Official Title: MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

Study ID: NCT02673021

Conditions

Metastatic Cancer to the Lung

Interventions

Microwave ablation

Study Description

Brief Summary: Does lung ablation improve clinical outcomes for patients deemed to be surgically high-risk?

Detailed Description: Surgical resection is the gold standard treatment for localized non-small cell lung cancer (NSCLC). However, surgery is invasive and not all patients are surgical candidates, thus providing an opportunity for percutaneous microwave ablation, for both primary and metastatic disease. Patients that are deemed inoperable are typically treated with other targeted therapies such as radiofrequency ablation (RFA), cryoablation and stereotactic body radiation therapy (SBRT), or systemic therapies. Percutaneous microwave ablation (MWA) is an alternative option for targeted treatment of cancer. Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue. Patients will be followed for 1 year by contrast enhanced chest CT, chest PET/CT and chest PET/MRI to evaluate lesion outcomes.